Top Markets
Coin of the day
Joinn Laboratories(China)Co.,Ltd. Joinn Laboratories(China)Co.,Ltd.

Joinn Laboratories(China)Co.,Ltd.

603127
Rank in Stocks #3550
Joinn Laboratories (China) Co., Ltd. delivers a comprehensive suite of... Joinn Laboratories (China) Co., Ltd. delivers a comprehensive suite of preclinical and non-clinical services to clients across the United States, China, and other international regions. The company's business is organized into three core operational areas. Its Non-Clinical Studies Services segment focuses on drug safety assessment, drug metabolism and pharmacokinetics analysis, and pharmacology and efficacy investigations. The Clinical Trial and Related Services division offers contract research organization (CRO) support for clinical trials, co-manages Phase I clinical research units, and provides bioanalytical services. Furthermore, the Sales of Research Models segment is involved in the design, production, breeding, and distribution of various research models, including non-human primates and rodents. Beyond these offerings, Joinn Laboratories also provides investment management and cell-based assay (CBA) services. Founded in 1995, the company is headquartered in Beijing, China.
Share Price
$6.83
Market Cap
$5.11B
Change (1 day)
-2.46%
Change (1 year)
52.90%
Country
CN
Trade Joinn Laboratories(China)Co.,Ltd. (603127)

Category

Earnings for Joinn Laboratories(China)Co.,Ltd. (603127)
Earnings in 2026 TTM: 0
According to Joinn Laboratories(China)Co.,Ltd. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Joinn Laboratories(China)Co.,Ltd. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$7.61B -
US
$4.76B -
US
- -
CN
$-252.70M -
US
$1.58B -
US